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Summary
Background The TARGIT-A trial compared risk-adapted radiotherapy using single-dose targeted intraoperative 
radiotherapy (TARGIT) versus fractionated external beam radiotherapy (EBRT) for breast cancer. We report 5-year 
results for local recurrence and the fi rst analysis of overall survival.
Methods TARGIT-A was a randomised, non-inferiority trial. Women aged 45 years and older with invasive ductal 
carcinoma were enrolled and randomly assigned in a 1:1 ratio to receive TARGIT or whole-breast EBRT, with 
blocks stratifi ed by centre and by timing of delivery of targeted intraoperative radiotherapy: randomisation 
occurred either before lumpectomy (prepathology stratum, TARGIT concurrent with lumpectomy) or after 
lumpectomy (postpathology stratum, TARGIT given subsequently by reopening the wound). Patients in the 
TARGIT group received supplemental EBRT (excluding a boost) if unforeseen adverse features were detected on 
fi nal pathology, thus radiotherapy was risk-adapted. The primary outcome was absolute diﬀ erence in local 
recurrence in the conserved breast, with a prespecifi ed non-inferiority margin of 2·5% at 5 years; prespecifi ed 
analyses included outcomes as per timing of randomisation in relation to lumpectomy. Secondary outcomes 
included complications and mortality. This study is registered with ClinicalTrials.gov, number NCT00983684.
Findings Patients were enrolled at 33 centres in 11 countries, between March 24, 2000, and June 25, 2012. 1721 patients 
were randomised to TARGIT and 1730 to EBRT. Supplemental EBRT after TARGIT was necessary in 15·2% [239 of 
1571] of patients who received TARGIT (21·6% prepathology, 3·6% postpathology). 3451 patients had a median 
follow-up of 2 years and 5 months (IQR 12–52 months), 2020 of 4 years, and 1222 of 5 years. The 5-year risk for local 
recurrence in the conserved breast was 3·3% (95% CI 2·1–5·1) for TARGIT versus 1·3% (0·7–2·5) for EBRT 
(p=0·042). TARGIT concurrently with lumpectomy (prepathology, n=2298) had much the same results as EBRT: 
2·1% (1·1–4·2) versus 1·1% (0·5–2·5; p=0·31). With delayed TARGIT (postpathology, n=1153) the between-group 
diﬀ erence was larger than 2·5% (TARGIT 5·4% [3·0–9·7] vs EBRT 1·7% [0·6–4·9]; p=0·069). Overall, breast cancer 
mortality was much the same between groups (2·6% [1·5–4·3] for TARGIT vs 1·9% [1·1–3·2] for EBRT; p=0·56) but 
there were signifi cantly fewer non-breast-cancer deaths with TARGIT (1·4% [0·8–2·5] vs 3·5% [2·3–5·2]; p=0·0086), 
attributable to fewer deaths from cardiovascular causes and other cancers. Overall mortality was 3·9% (2·7–5·8) for 
TARGIT versus 5·3% (3·9–7·3) for EBRT (p=0·099). Wound-related complications were much the same between 
groups but grade 3 or 4 skin complications were signifi cantly reduced with TARGIT (four of 1720 vs 13 of 1731, 
p=0·029).
Interpretation TARGIT concurrent with lumpectomy within a risk-adapted approach should be considered as an 
option for eligible patients with breast cancer carefully selected as per the TARGIT-A trial protocol, as an alternative 
to postoperative EBRT.
Funding University College London Hospitals (UCLH)/UCL Comprehensive Biomedical Research Centre, UCLH 
Charities, National Institute for Health Research Health Technology Assessment programme, Ninewells Cancer 
Campaign, National Health and Medical Research Council, and German Federal Ministry of Education and Research.
Introduction
Adjuvant whole-breast external beam radiotherapy 
(EBRT) is deemed mandatory after lumpectomy for 
breast cancer on the basis of the reduction of local 
recurrence in the conserved breast and of breast cancer 
mortality.1 Even in highly selected patients, omission of 
radiotherapy increases the risk of local recurrence.2–5
To develop a more refi ned and personalised approach to 
adjuvant radiotherapy, we designed the TARGIT-A 
(TARGeted Intraoperative radioTherapy Alone) trial.6 The 
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experimental intervention (risk-adapted radiotherapy) 
consisted of one dose of radiation to the tumour bed 
using targeted intraoperative radiotherapy (also known as 
TARGIT), supplemented when necessary by EBRT in 
patients in whom unforeseen risk factors were discovered 
on the fi nal pathology report. The control intervention 
was standard treatment, consisting of several weeks of 
whole-breast EBRT. 
The TARGIT-A trial was originally conceived7–9 as a 
response to a clinical dilemma and a clinicopathological 
paradox. The clinical dilemma is faced by many patients 
with limited access to radiotherapy. Many such patients, 
presenting with breast cancer suitable for breast-
conserving surgery but unable to attend daily for up to 
6 weeks for postoperative radiotherapy, will face 
mastectomy. Even in the USA, women living far from a 
radiotherapy centre do not receive optimum breast-
conserving therapy.10 Where access is easy, the prolonged 
course can be stressful and inconvenient. If a one-oﬀ  
radiation treatment at the time of surgery could be shown 
to be non-inferior to EBRT, then many women worldwide 
might avoid the protracted course of EBRT and many 
might be spared an unnecessary mastectomy. At the very 
least, one-oﬀ  radiation treatment would signifi cantly 
shorten treatment time and improve patient experience.
The clinicopathological paradox that led to the idea of 
focusing radiation to the tumour bed was motivated by 
the repeated observation that although two-thirds of 
specimens of mastectomies undertaken for small breast 
cancers harbor occult cancer foci distributed throughout 
the breast,7–9,11 most local recurrences in the conserved 
breast appear in the original tumour bed.7–9
This investigator-initiated trial was launched in March, 
2000, and reached the original accrual goal of 2232 
participants in April, 2010. In July, 2010, when we 
reported the initial results for local control and early 
complications,6 the 4-year Kaplan-Meier estimate of local 
recurrence in the conserved breast was 1·20% (95% CI 
0·53–2·71) for those randomised to TARGIT and 0·95% 
(0·39–2·31) for those randomised to EBRT. A second 
analysis was planned after a further 2 years of follow-up. 
We continued randomisation until June, 2012, to allow 
accrual in sub-protocols while the data matured further, 
and closed the trial after accruing the planned 1200 
additional patients (1219 accured, total n=3451). In the 
present report, we provide updated analyses and 5-year 
estimates for local control and the fi rst analysis of overall 
survival. Additionally, we investigated whether the 
timing of TARGIT in relation to lumpectomy made a 
diﬀ erence to the outcome.
Methods
Procedures
As previously described,6 women with early breast 
cancer were eligible if they were aged 45 years or 
older and suitable for wide local excision for invasive 
ductal carcinoma that was unifocal on conventional 
examination and imaging. MRI was not required and 
only 5·6% (192) of patients in the trial had an MRI 
performed. Patients gave written informed consent to 
join the trial. The protocol was approved by the appro-
priate regulatory and ethics authorities for each centre 
before enrolment could begin.
Patients were randomly assigned in a 1:1 ratio to receive 
a risk-adapted approach using single-dose TARGIT or 
EBRT as per standard schedules over several weeks, with 
randomisation blocks stratifi ed by centre and by proposed 
timing of delivery of TARGIT (prepathology and post-
pathology strata; appendix); details have been described 
previously.6 A risk-adapted approach meant that if the 
fi nal pathology report showed unpredicted prespecifi ed 
adverse features, then EBRT was to be added to TARGIT, 
in which case TARGIT served as the tumour-bed boost. 
The core protocol defi ned three such features when 
EBRT was recommended to supplement TARGIT within 
the experimental group: tumour-free margin smaller 
than 1 mm, extensive in-situ component, or unexpected 
invasive lobular carcinoma. Pragmatically, individual 
centres could prespecify more than these core factors, 
such as close margins (eg, 1–10 mm) or other adverse 
prognostic factors (eg, several positive nodes, extensive 
lymphovascular invasion) in a treatment policy document 
before they started recruitment. Therefore, the trial was a 
comparison of two policies—so called one-size-fi ts-all 
whole-breast radiotherapy versus individualised risk-
adapted therapy—in which a proportion of patients who 
received TARGIT were also given EBRT if they were 
shown to have adverse tumour factors. This situation was 
expected in 15% of cases and was incorporated into the 
power calculations. Sample size calculations have been 
described previously.6 All analyses were by intention to 
treat. A summary of the protocol and the full protocol are 
available online.
The concept and the TARGIT technique, which was 
pioneered by investigators at University College London,12–14 
allows the patient to receive all required radiation in one 
fraction before she awakes from surgery (appendix).12–21 
The Intrabeam device (Carl Zeiss Meditec, Oberkochen, 
Germany) provides a point source of 50 kV energy x-rays at 
the centre of a spherical applicator. The appropriately sized 
(1·5–5·0 cm diameter) applicator is placed in the tumour 
bed using a meticulous surgical technique, including a 
carefully inserted purse-string suture that ensures that 
breast tissues at risk of local recurrence receive the 
prescribed dose while skin and deeper structures are 
protected. Radiation is delivered over 20–45 min to the 
tumour bed. The surface of the tumour bed typically 
receives 20 Gy that attenuates to 5–7 Gy at 1 cm depth.
In the initial trial design, randomisation to TARGIT 
or EBRT group was done before lumpectomy (pre-
pathology). However, the trial was also fi rmly rooted on 
the principles of pragmatism to test a new approach 
(single dose targeted intraoperative radiotherapy to 
the tumour bed followed by EBRT in patients with 
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unforeseen adverse factors). Therefore, when some of 
the centres planning to join the trial requested us to 
allow them to give intraoperative radiotherapy as a 
second procedure by reopening the wound, we per-
mitted it: this decision facilitated more stringent 
selection of patients (tumour pathology was available—
hence postpathology) and was logistically easier, allow-
ing enrolment of patients from neighbouring centres 
who had already had the lumpectomy. We therefore 
made a protocol amendment on Sept 22, 2004, obtained 
ethics approval, and added this postpathology stratum 
to the trial, along with a completely separate random-
isation table for such patients.
We specifi ed that postpathology patients should be 
randomised within 30 days after lumpectomy. If 
allocated to TARGIT, patients in the prepathology 
stratum received it concurrently, immediately after 
surgical excision under the same anaesthesia; patients 
in the postpathology stratum received it as a subsequent 
procedure. We planned a separate analysis of the two 
strata (prepathology vs postpathology). The rationale for 
stratifi cation according to the scheduling of radio-
therapy was that randomisation to the trial after full 
pathology had become available might theoretically 
allow better case selection. Conversely, treatment given 
at the time of initial lumpectomy could have a greater 
eﬀ ectiveness because of its immediacy. Furthermore, 
the degree of accuracy of placement of the radiotherapy 
applicator for giving TARGIT by reopening the cavity 
might be quite diﬀ erent from that achieved at the time 
of original lumpectomy.
The primary outcome measure was the absolute 
diﬀ erence in local recurrence in the conserved breast in 
patients who had received breast-conserving therapy. 
Power calculations were based on this outcome measure 
for an absolute non-inferiority margin of 2·5% (as 
detailed in section 9 of the protocol) and the original 
recruitment goal was 2232 patients in total. The 
secondary outcomes were toxicity and overall survival, 
including breast-cancer deaths and non-breast-cancer 
deaths. An independent senior clinician, masked to 
randomisation, reviewed the available data and 
ascertained the cause of death in all cases. If breast 
cancer was present at the time of death, the death was 
presumed to be from breast cancer. We prespecifi ed a 
formal analysis for deaths from cardiovascular causes 
and deaths from other cancers.
We did exploratory analyses for regional recurrence 
(axilla plus supraclavicular), loco-regional recurrence 
(local plus regional), distant recurrence, any other 
recurrence (regional, contralateral breast, and distant 
recurrence), and all recurrence (local recurrence in the 
conserved breast and any other recurrence).
Early complications were published previously6 and for 
this report, we analysed complications arising 6 months 
after randomisation. This trial is registered with 
ClinicalTrials.gov, number NCT00983684.
Statistical analysis
We analysed the non-inferiority statistic by calculating 
the diﬀ erence in binomial proportions of local recur-
rences in the conserved breast between the two random-
ised groups (TARGIT vs EBRT). To assess stability over 
time, we also calculated this statistic for the mature 
cohort (n=2232), reported in 2010, and for the earliest 
cohort (excluding the last 4 years of enrolment; n=1222) 
who had a median follow up of 5 years. We calculated the 
Z score and pnon-inferiority using established methods22–24 for 
the whole cohort and the two prespecifi ed strata—
prepathology and postpathology.
To address the issue of follow-up, we charted the 
absolute diﬀ erences in the 5-year Kaplan-Meier estimates 
of local recurrence in the conserved breast and overall 
mortality for patients with prepathology randomisation 
in the whole trial along with the mature cohort reported 
in 2010, which has a longer follow up (median 3 years 
8 months, maximum 12 years), and the earliest cohort.
A patient was deemed to have adequate follow-up if 
they had at least 5 years of follow-up or if they were seen 
within the year before database lock. Patients were 
censored when they were last seen or withdrawn from 
the trial. The database (customised Microsoft Access) as 
validated on June 29, 2012, was used for this analysis, 
with June 1, 2012, as a reference date. SAS System 
(version 9.3), Excel 2011, STATA (version 12.0), and SPSS 
(version 20.0) were used for data compilation, validation, 
and analysis. Kaplan-Meier graphs were displayed as 
recommended by Pocock and colleagues,25 and a log-rank 
test was used to compare the diﬀ erence between survival 
function and to obtain p values (signifi cance level set at 
p<0·01 for local recurrence and p<0·05 for survival).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author and the 
trial statistician had full access to all the data in the study; 
all authors were responsible for the decision to submit 
for publication.
Results
The trial recruited 3451 patients from 33 centres in 
11 countries from March 24, 2000, to June 25, 2012; 
1721 patients were randomly allocated to TARGIT and 
1730 to EBRT. Two thirds of patients (n=2298) were 
randomised before lumpectomy (prepathology) and a 
third (n=1153) were randomised after lumpectomy (post-
pathology). As per protocol, of those who received 
TARGIT, 15·2% (239 of 1571) received both TARGIT and 
EBRT (21·6% [219 of 1012] in the prepathology stratum 
and 3·6% [20 of 559] in the postpathology stratum).
Since the 2010 analysis, the number of primary events 
has increased from 13 to 34. There have been 88 deaths, 
36 from breast cancer and 52 from causes other than 
breast cancer.
Articles
4 www.thelancet.com   Vol 382   Published online November 11, 2013   http://dx.doi.org/10.1016/S0140-6736(13)61950-9
The patient and tumour characteristics and trial profi le 
are in the appendix. The risk-adapted design is shown in 
the trial profi le—eg, of the 1140 patients allocated TARGIT 
in the prepathology stratum, 219 received TARGIT and 
EBRT as per protocol, because they were shown to 
have characteristics of high-risk disease postoperatively 
(appen dix). There was no signifi cant diﬀ erence between 
prepathology and postpathology in the timing of delivery 
of EBRT (p=0·58). Most cancers were small and of good 
prognosis (87% [2685 of 3082] were up to 2 cm, 85% 
[2573 of 3032] grades 1 or 2, 84% [2610 of 3112] node 
negative, 93% [2874 of 3093] oestrogen-receptor positive 
and 82% [2462 of 3016] progesterone-receptor positive) 
and detected by screening 69% [2102 of 3063]. The appen-
dix shows tumour characteristics and main results as per 
treatment received.
93·7% [3234 of 3451] of patients were seen within the 
year before datalock or had at least 5 years of follow-
up (appendix). The whole cohort of 3451 patients 
had a median follow-up of 2 years and 5 months 
(IRQ 12–52 months), 2020 patients had a median follow-
up of 4 years, and 1222 patients had a median follow-up 
of 5 years. The mature cohort of 2232 patients, which was 
originally reported in 2010, had a median follow up of 
3 years and 7 months (IRQ 30–61 months).
Table 1 shows detailed results for the local recurrence 
in the conserved breast (primary outcome), any other 
recurrence (exploratory outcome), and death (secon-
dary outcome).
The 5-year risks for local recurrence in the conserved 
breast for TARGIT versus EBRT were 3·3% (95% CI 
2·1–5·1) versus 1·3% (0·7–2·5; p=0·042). Breast cancer 
mortality was much the same in the two groups: 2·6% 
(1·5–4·3) for TARGIT versus 1·9% (1·1–3·2) for EBRT 
(p=0·56), but there were signifi cantly fewer non-breast-
cancer deaths in the TARGIT group than the EBRT 
group (1·4%, 0·8–2·5 vs 3·5%, 2·3–5·2; p=0·0086), 
attributable to fewer deaths from cardiovascular causes 
and other cancers (fi gure 1, table 2). Overall mortality for 
TARGIT was 3·9% (2·7–5·8) versus 5·3% (3·9–7·3) for 
EBRT (p=0·099). Overall, in absolute terms, there were 
12 additional local recurrences but 14 fewer deaths in the 
TARGIT group (fi gures 1, 2).
Despite the poor prognostic factors for survival in the 
group selected to receive TARGIT plus EBRT, as shown 
by the increased breast cancer mortality (8·0%, 95% CI 
3·5–17·5), local recurrence was low in that group (0·9%, 
0·1–6·1), and did not diﬀ er from those who received 
TARGIT alone (appendix).
In the prepathology stratum—ie, when TARGIT was 
delivered during the initial lumpectomy, 2298 patients—
the risk of local recurrence in the conserved breast was 
much the same for TARGIT as for EBRT: TARGIT 2·1% 
(95% CI 1·1–4·2) versus EBRT 1·1% (0·5–2·5; p=0·31). 
Breast-cancer mortality was 17 patients for TARGIT 
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Figure 1: Kaplan-Meier analysis of breast cancer deaths and non-breast-cancer deaths
(A) Breast cancer. (B) Non-breast-cancer. TARGIT=targeted intraoperative radiotherapy. EBRT=external beam radiotherapy.
Events; 5-year cumulative risk (95%CI) Absolute diff erence*
TARGIT EBRT
All patients
Local recurrence (n=3375) 23; 3·3% (2·1–5·1) 11; 1·3% (0·7–2·5) 12 (2·0%)
Any other recurrence (n=3375) 46; 4·9% (3·5–6·9) 37; 4·4% (3·0–6·4) 9 (0·5%)
Death (n=3451) 37; 3·9% (2·7–5·8) 51; 5·3%(3·9–7·3) –14 (–1·4%)
Prepathology†
Local recurrence (n=2234) 10; 2·1% (1·1–4·2) 6; 1·1% (0·5–2·5) 4 (1·0%)
Any other recurrence (n=2234) 29; 4·8% (3·1–7·3) 25; 4·7% (3·0–7·4) 4 (0·1%)
Death (n=2298) 29; 4·6% (1·8–6·0) 42; 6·9% (4·3–9·6) –13 (–2·3%)
 Postpathology‡
Local recurrence (n=1141) 13; 5·4% (3·0–9·7) 5; 1·7%(0·6–4·9) 8 (3·7%)
Any other recurrence (n=1141) 17; 5·2% (3·0–8·8) 12; 3·7% (1·9–7·0) 5 (1·5%)
Death (n=1153) 8; 2·8% (1·3–5·9) 9; 2·3% (1·0–5·2) –1 (0·5%)
TARGIT=targeted intraoperative radiotherapy. EBRT=external beam radiotherapy. *In Kaplan-Meier point estimate at 
5 years (TARGIT minus EBRT). †TARGIT given at same time as lumpectomy. ‡TARGIT given after lumpectomy, as 
separate procedure. 
Table 1: Results of primary (local recurrence in the conserved breast), secondary (death), and exploratory 
(any other recurrence) outcomes for all patients and the two strata as per timing of randomisation and 
delivery of TARGIT
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versus 15 patients for EBRT (3·3%, 1·9–5·8 vs 2·7%, 
1·5–4·6; p=0·72), non-breast-cancer mortality was 
12 patients for TARGIT versus 27 patients for EBRT 
(1·3%, 0·7–2·8% vs 4·4%, 2·8−6·9; p=0·016). Thus, in 
absolute terms, there were four additional local 
recurrences but 13 fewer deaths in the prepathology 
TARGIT stratum (fi gure 3; appendix).
In the postpathology stratum—ie, when TARGIT was 
delivered as a delayed procedure by reopening the 
lumpectomy cavity, 1153 patients—the diﬀ erence in local 
recurrence in the conserved breast between the two groups 
was larger than 2·5%: TARGIT 5·4% (95% CI 3·0–9·7) vs 
EBRT 1·7% (0·6–4·9; p=0·069). Breast-cancer mortality 
was three patients for TARGIT versus one patient for 
EBRT (1·2%, 0·4–4·2 vs 0·5%, 0·1–3·5; p=0·35), and non-
breast-cancer mortality was fi ve patients for TARGIT 
versus eight patients for EBRT (1·58%, 0·62–3·97 vs 
1·76%, 0·7–4·4; p=0·32). Thus, in absolute terms, there 
were eight additional local recurrences and one less death 
in the postpathology TARGIT stratum (fi gure 3).
The results of a comparison26 of cumulative incidence 
for local recurrence in the presence of competing risks 
(death and withdrawal from trial) were no diﬀ erent from 
Kaplan-Meier estimates, showing that these risks did not 
bias the main results (data not shown).
Analysis limited to the mature cohort, fi rst reported in 
2010 (n=2232, median follow-up now 3 years 7 months), 
in which most events had occurred (32 of 34 local 
recurrences and 85 of 88 deaths), yielded much the same 
results (data not shown).
Table 3 shows the Z score and pnon-inferiority for the primary 
outcome of local recurrence in the conserved breast, for 
the whole cohort, the mature cohort, and the earliest 
cohort. Non-inferiority is established for the whole 
cohort and for prepathology patients but not for post-
pathology patients.
Figure 4 shows the primary (local recurrence in the 
conserved breast) and secondary outcomes (deaths) for 
the prepathology stratum. It shows the diﬀ erences in 
5-year estimates for these outcomes for the whole cohort, 
the mature cohort, and the earliest cohort. It demonstrates 
the stability of the results with longer follow-up and the 
trade-oﬀ s between the two outcomes.
For the secondary outcome of complications 6 months 
after randomisation, we noted no signifi cant diﬀ erence 
in any protocol-defi ned wound-related complication. 
There were fewer grade 3 or 4 radiotherapy-related skin 
complications with TARGIT than with EBRT (four of 
1721 vs 13 of 1730, p=0·029).
In post-hoc exploratory analyses, we noted no sig-
nifi cant diﬀ erence in 5-year risk of regional recurrence 
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Figure 2: Kaplan-Meier analysis of local recurrence in the conserved breast, 
regional recurrence (axillary and supraclavicular), and deaths
Local recurrence was the primary outcome, death was a secondary outcome, 
regional recurrence was an exploratory outcome. Three of the 14 regional 
recurrences had breast recurrence as well (one TARGIT and two EBRT). (A) Local 
recurrence in the conserved breast. (B) Regional recurrence. (C) Death. 
TARGIT=targeted intraoperative radiotherapy. EBRT=external beam radiotherapy.
TARGIT EBRT
Other cancers 8 16
Cardiovascular causes
Cardiac* 2 8
Stroke 0 2
Ischaemic bowel 0 1
Other† 7 8
Total 17 35
5-year risk 1·4% for TARGIT versus 3·5% for EBRT; log-rank p=0·0086. 
TARGIT=targeted intraoperative radiotherapy. EBRT=external beam radiotherapy. 
*Included one “sudden death at home” in EBRT group. †TARGIT: two diabetes, 
one renal failure, one liver failure, one sepsis, one Alzheimer’s disease, one 
unknown; EBRT: one myelopathy, one perforated bowel, one pneumonia, one old 
age, four unknown.
Table 2: Causes of death other than breast cancer in all patients
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(1·1%, 95% CI 0·5–2·1 for TARGIT vs 0·9%, 0·4–2·2 for 
EBRT), distant recurrence (3·9%, 2·7–5·6 vs 3·2%, 
2·1–4·9), any other recurrence (4·9%, 3·5–6·9 vs 4·4%, 
3·0–6·4), or all recurrence (8·2%, 6·3–10·6 vs 5·7%, 
4·1–7·8). The diﬀ erence in all recurrence, which was 
driven by local recurrence in the conserved breast, was 
smaller in the prepathology stratum (6·9%, 4·8–9·8 vs 
5·8%, 3·9–8·5) than in the postpathology stratum 
(10·4%, 7·0–15·2 vs 5·4, 3·1–0·2). Similarly, the diﬀ er-
ence in loco-regional recurrence 4·2% (2·8–6·1) for 
TARGIT versus EBRT 2·0% (1·1–3·5) was smaller in the 
prepathology stratum (3·1%, 1·8–5·2 vs 2·0%, 1·0–4·0) 
than the the postpathology stratum (6·2%, 3·6–10·6 vs 
2·0%, 0·8–5·2).
Discussion
At 5 year follow-up, risk of local recurrence with TARGIT 
was non-inferior to EBRT when all patients were analysed 
together.  Analysis of the two strata according to timing 
of delivery of TARGIT confi rmed non-inferiority when 
TARGIT was delivered concurrently with lumpectomy 
(prepathology stratum) but not in the postpathology 
stratum, in which TARGIT was given as a second 
procedure after reopening the wound. Overall, breast-
cancer mortality was much the same for TARGIT and 
EBRT, but signifi cantly fewer non-breast-cancer deaths 
occurred in the TARGIT group than the EBRT group, 
attributable to fewer deaths from cardiovascular causes 
and other cancers. Wound-related complications were 
much the same between the groups, but there were 
signifi cantly fewer grade 3 or 4 radiotherapy-related 
complications with TARGIT than with EBRT. The main 
outcomes remained stable in cohorts of patients with 
increasing median follow-up periods (fi gure 4).
We emphasise that this trial is of a risk-adapted design: 
it is a trial of two policies, not of TARGIT versus EBRT. 
The aim in the experimental group was to complete 
therapy with one radiation treatment delivered at the 
time of surgery in most patients, but if subsequent 
pathology suggested adverse histological features then it 
was mandatory to complete treatment to the whole 
breast (but omitting a tumour-bed radiation boost). This 
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Figure 3: Kaplan-Meier analysis of local recurrence in the conserved breast and death for the two strata as per timing of randomisation and delivery of TARGIT 
(prepathology vs postpathology)
Local recurrence was the primary outcome, death was a secondary outcome. Prepathology (n=2298), randomised before lumpectomy and TARGIT given concurrently 
with lumpectomy. Postpathology (n=1153), randomised after lumpectomy and TARGIT given by reopening the wound. (A) Local recurrence in prepathology stratum. 
(B) Deaths in prepathology stratum. (C) Local recurrence in postpathology stratum. (D) Deaths in postpathology stratum. TARGIT=targeted intraoperative 
radiotherapy. EBRT=external beam radiotherapy. 
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scenario occurred in 15% of cases as per our original 
estimate. Because the allocation of treatment was ran-
domised, about the same percentage of patients with 
adverse pathology would be included in the TARGIT and 
EBRT groups. This trial therefore has a true pragmatic 
design, reflecting practice in the real world, while 
maintaining statistical validity. The addition of EBRT in 
the TARGIT group is not a crossover or a protocol 
deviation but was prospectively required in the protocol.
The prepathology and postpathology divisions were not 
subgroups based on patient or tumour characteristics; 
they were two distinct strata, as per the timing of 
randomisation (either before or after lumpectomy), and 
therefore delivery of TARGIT (either concurrently with 
the initial lumpectomy under the same anaesthetic or as a 
second separate procedure). They had diﬀerent methods 
of case selection, separate randomisation tables, and 
diﬀerent methods of giving the experimental treatment 
(fresh wound vs reopened wound). Individual separate 
analysis of each of these two strata was prespecified, and 
the two could be considered as parallel trials.
Length of follow-up did not diﬀer between the pre-
pathology and postpathology strata, because although the 
postpathology randomisation started a few years later 
than the prepathology stratum, accrual was slow in the 
first few years and only about 5% of all patients were 
recruited before postpathology randomisation was 
started; hence the diﬀerence in median follow-up was 
only 1 month.
The original mature cohort of 2232 patients,6 included 
within this analysis, has a median follow up of close to 
4 years (and 1222 of these patients have a median follow 
up of 5 years), thus covering the period of the peak 
hazard for breast cancer local recurrent events that seem 
to cluster around 2–3 years.27 Furthermore, since the first 
report,6 the number of primary events has increased 
from 13 to 34.
Although the original power calculations needed 
2232 patients for the trial, we have previously explained 
how with a background recurrence rate of 1·5% a trial 
testing for a non-inferiority margin of 2·5% with 80% 
power and 95% confidence needs a sample size of only 
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Figure 4: Absolute differences in 5-year Kaplan-Meier estimate of local 
recurrence in the conserved breast and overall mortality (TARGIT minus 
EBRT) for the prepathology stratum in the whole cohort, the mature cohort 
and the earliest cohort
All patients in the earlier cohorts are included in later cohorts. Median follow-up 
for whole cohort was 2 years 4 months. Median follow-up for mature cohort was 
3 years 8 months. Median follow-up for earliest cohort was 5 years. 
TARGIT=targeted intraoperative radiotherapy. EBRT=external beam radiotherapy.
Median follow-up Number of events Absolute difference (90% CI) 
in the binomial proportions of 
local recurrence* in the 
conserved breast (TARGIT 
minus EBRT)
Z score pnon–inferiority
Whole trial
All patients (n=3451) 2 years 5 months 34 0·72% (0·2 to 1·3) –5·168 <0·0001
Mature cohort (n=2232) 3 years 7 months 32 1·13% (0·3 to 2·0) –2·652 0·0040 
Earliest cohort (n=1222) 5 years 23 1·14% (–0·1 to 2·4) –1·750 0·0400 
Prepathology†
All patients (n=2298) 2 years 4 months 16 0·37% (–0·2 to 1·0) –5·954 <0·0001
Mature cohort (n=1450) 3 years 8 months 14 0·6% (–0·3 to 1·5) –3·552 0·0002
Earliest cohort (n=817) 5 years 9 0·76% (–0·4 to 2·0) –2·360 0·0091
Postpathology‡
All patients (n=1153) 2 years 4 months 18 1·39% (0·2 to 2·6) –1·503 0·0664
Mature cohort (n=782) 3 years 7 months 18 2·04% (0·3 to 3·8) –0·429 0·3339
Earliest cohort (n=405) 5 years 14 1·8% (–1·2 to 4·8) –0·382 0·3511
The prespecified non-inferiority margin was 2·5%. Mature cohort consisted of 2232 patients for whom data was previously reported in 2010. Earliest cohort excluded 
patients enrolled in the last 4 years of the study. TARGIT=targeted intraoperative radiotherapy. EBRT=external beam radiotherapy. *Binomial proportion=number of 
recurrences/number of patients. †TARGIT given at same time as lumpectomy. ‡TARGIT given after lumpectomy, as separate procedure. 
Table 3: Calculation of pnon-inferiority for the whole cohort, the mature cohort, and the earliest cohort
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585.6 We have 2298 patients in the prepathology stratum 
and 1153 patients in the postpathology stratum and we 
have 1222 patients with a median follow-up of 5 years.
We can be assured that there is no increased toxicity with 
TARGIT, and radiotherapy-related local toxic eﬀ ects are 
slightly reduced. The low incidence of grade 3 or grade 4 
radiotherapy-related toxic eﬀ ects and local recurrences is 
also indicative of the high-quality radiotherapy being given 
in the EBRT group. Previous studies from individual 
centres have suggested a better cosmetic outcome,28 lower 
short-term and long-term skin toxicity, and better quality of 
life with TARGIT.29,30 In a separate comparison no diﬀ er-
ence was shown between the toxicity of TARGIT plus 
EBRT versus EBRT with EBRT boost.30
We had not planned a statistical test comparing the 
EBRT groups in the two strata with each other, since 
this would have been a non-randomised comparison. 
Nevertheless, the apparent diﬀ erence in non-breast-
cancer deaths between the EBRT groups in the two pre-
pathology and postpathology strata is not statistically 
signifi cant (p=0·17).
Cause-specifi c mortality was much the same in the two 
groups but there were signifi cantly fewer non-breast-
cancer deaths in the TARGIT group (p=0·0086). This 
diﬀ erence was mainly attributable to fewer (two vs 11) 
deaths from cardiovascular causes and new non-breast 
cancers (eight vs 16; fi gure 1, table 2). Although an 
increase in cardiovascular deaths related to radiotherapy1 
has not previously become apparent for 7–10 years31 a 
large study that included patients treated until 2001, has 
shown that signifi cant radiotherapy-related cardiac 
toxicity is apparent within the fi rst 4 years.32 Importantly, 
in the TARGIT-A trial, 1222 patients have a median 
follow up of 5 years, and the statistical probability that 
the diﬀ erence we have identifi ed has arisen by pure 
chance is low (p=0·0086). Data for comorbidities were 
not collected at the time of randomisation. However, we 
believe that with such a large trial size (n=3451) it is 
improbable that there was a substantial imbalance in 
baseline comorbidities between the two randomised 
groups of the trial. We shall continue monitoring for 
deaths, because longer follow-up would allow further 
validation of the mortality fi ndings.
Several diﬀ erent approaches for partial breast irra-
diation or accelerated partial breast irradiation are 
currently in clinical practice or in clinical studies and 
have been reviewed elsewhere.33 All partial breast 
irradiation techniques share the concept of restriction of 
the radiation to the tumour bed, but only the TARGIT-A 
trial has studied the addition of EBRT if adverse risk 
factors are present. Radiobiological studies suggest that 
one or a few fractions of larger doses, delivered to a small 
volume in a shorter overall treatment time, increases the 
biologically equivalent dose, and this notion is supported 
by clinical data.16,34,35 Furthermore, studies suggest that 
the relative biological eﬀ ectiveness of TARGIT is 1·2–1·4 
at 8 mm depth.35
The only other randomised trial testing intraoperative 
partial breast radiotherapy is the ELIOT (intraoperative 
radiotherapy with electrons) trial,36 but the techniques 
are fundamentally diﬀ erent. Whereas TARGIT delivers 
radiation from within the undisturbed tumour bed, for 
ELIOT, the mammary gland is mobilised, a prepectoral 
lead shield is inserted, the edges of the tumour bed are 
apposed, and radiation is delivered from without. 
TARGIT uses 50 kV x-rays delivering 20 Gy to the tumour 
bed surface and 5–7 Gy at 1 cm depth, in 20–45 min (set 
up time 10 min). ELIOT uses electrons at 4–12 MeV 
delivering 21 Gy in 3–5 min (set up time 20 min).
Several factors might have played a part in achieving 
the low recurrence rates that we have identifi ed in the 
stratum randomised to receive TARGIT immediately 
after lumpectomy. These factors include immediate 
delivery of radiation to well vascularised tissues at the 
right time and delivery of an optimum dose to the 
minimum required volume of target tissue at a dose rate 
that would allow normal tissue to repair, as well as 
addition of EBRT when high-risk factors were identifi ed 
postoperatively. In the postpathology stratum this 
advantage of immediate placement of the radiotherapy 
applicator directly in the fresh tumour bed seems to be 
lost (median time between primary surgery and post-
pathology TARGIT treatment was 37 days), along with its 
benefi cial eﬀ ects on the tumour micro environment,37,38 
and this diﬀ erence might have contributed to the higher 
recurrence rate in that stratum. It could be argued that 
the patients in the prepathology stratum might have 
done just as well without radiotherapy; however, this 
study provides its own internal control: the patients in 
the postpathology stratum were highly selected for 
favourable pathological entry criteria yet they showed a 
signifi cant diﬀ erence of 3·7% (5·4% vs 1·7%) in local 
recurrence, much the same as for patients in studies 
with a non-irradiated experi mental group.39,40 In the pre-
pathology stratum the diﬀ erence was only 1·0%, 
suggesting that TARGIT is eﬀ ective in reducing local 
recurrence when given concurrently with lumpectomy.
When TARGIT was given concurrently with lump-
ectomy, the (non-signifi cant) absolute diﬀ erence in local 
recurrence between the two randomised groups remains 
within the prespecifi ed non-inferiority margin, and this 
approach would be our preferred option. We emphasise 
that this result is obtained from an analysis of a 
prespecifi ed stratum, classifi ed by the timing of random-
isation in relation to lumpectomy (prepathology), without 
restricting the analysis to any particular age group or 
biological subtype. Studies examining patient preference 
confi rm that this level of diﬀ erence will also be acceptable 
to most patients.41,42 The satisfactory local control rate 
shown in the prepathology stratum is obtained using a 
pragmatic protocol in which about one in fi ve women 
had EBRT in addition to TARGIT. While the need 
for supplemental EBRT might have been disappointing 
for these individual women, most women in the 
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prepathology stratum (about 80%) avoided having to 
attend for several weeks of EBRT.
Although it is possible that with longer follow-up the 
postpathology stratum might eventually do as well as the 
larger prepathology stratum, in view of the present 
results we wish to exercise caution and only support the 
use of TARGIT concurrent with lumpectomy, for which 
there is no signifi cant diﬀ erence between the randomised 
groups (n=2298) in respect of local recurrence.
In practice, individual women should be allowed to 
make the choice between treatment options when 
presented with robust evidence and the relevant trade-
oﬀ s. To facilitate this decision making, and to show the 
stability of the results, we charted the main results for 
the prepathology stratum in fi gure 4, which gives the 
absolute diﬀ erences in the 5-year risks of local recurrence 
in the conserved breast and overall mortality for whole 
cohort, the mature cohort6 with longer median follow-up 
close to 4 years, and the earliest cohort with a median 
follow-up of 5 years. First, this fi gure suggests that any 
diﬀ erence between TARGIT and EBRT for local 
recurrence and overall mortality remains stable with 
longer follow-up. Second, it shows the trade-oﬀ  between 
these two important outcomes, and could facilitate 
counselling patients about TARGIT. When TARGIT is 
given concurrently with lumpectomy, there is a 1% 
increase in local recurrence (from 99% to 98% chance of 
being free of local recurrence) along with a potential 
2·3% decrease in overall mortality (from 93·1% to 95·4% 
chance of being alive) at 5 years.
Omission of radiotherapy in a low-risk group of 
patients already receiving endocrine therapy might not 
increase breast cancer mortality, but it does increase local 
recurrence by a small but signifi cant amount: an absolute 
increase of about 7% at 5 years overall,3,43 and about 8% at 
10 years, even in patients older than 70 years.5 Therefore, 
achieving local control (local recurrence down to 2% at 
5 years) while minimising the cost and reducing toxicity 
(local toxicity and non-breast-cancer mortality) that is 
noted with conventional radiotherapy32 by use of TARGIT 
concurrently with lumpectomy would seem a worth-
while goal. Since these results give confi dence about the 
applicability of TARGIT to patients who fulfi l the 
eligibility criteria of the TARGIT-A trial, there should be 
little hesitation in oﬀ ering this treatment to selected 
patients with a good prognosis (eg, those deemed suitable 
by the European Society for Radiotherapy and Oncology44 
or American Society for Radiation Oncology45 criteria).
The projected cost-saving with TARGIT has previously 
been estimated to be in the region of several million 
pounds in the UK46 and substantially more in the USA,47 
even without including time-savings and cost-savings to 
the patient.
The most important benefi t of TARGIT for a woman 
with breast cancer is that it allows her to complete her 
entire local treatment at the time of her operation, with 
lower toxicity. If these results are to be applied to everyday 
practice, we wish to emphasise that the selection of 
patients must adhere to the eligibility criteria in the trial, 
and we would favour the prepathology (concurrent) 
approach over the delayed approach (panel). Importantly, 
the risk-adapted design of the TARGIT group must be 
followed—ie, when higher risk factors are found 
postoperatively, EBRT should be added. Ultimately, we 
believe that these data should allow patients and their 
clinicians to make a more informed choice about 
individualising their treatment.
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Panel: Research in context
Systematic review
We searched PubMed on July 21, 2013, with no restriction of date or language, using the 
terms “randomised”, “breast”, “cancer”, “intraoperative”, and “radiation” or “radiotherapy” to 
identify randomised trials comparing postoperative whole-breast irradiation with 
intraoperative radiotherapy after breast conserving surgery for breast cancer. Although in 
the past 15 years there has been much interest in this treatment, as shown by the large 
number of phase 1 and 2 trials, we identifi ed only two techniques in phase 3 trials: TARGIT 
and ELIOT (intraoperative radiotherapy with electrons). We did not include other methods of 
giving partial breast irradiation.
We are awaiting publication of the results of the ELIOT trial (n=1300) in which intraoperative 
radiotherapy was given with a mobile linear accelerator (NOVAC-7) delivering 21 Gy by 
placing a cylindrical applicator onto a reconstructed tumour bed.
With the TARGIT technique, one dose of 20 Gy to the tumour bed is delivered by placing a 
spherical applicator within it. This technique could be done either immediately after the 
lumpectomy during the same anaesthetic (prepathology) or as a second procedure (with 
randomisation done after pathological examination of the specimen leading to tighter 
case selection—postpathology) by reopening the wound. The two types of delivery were 
two separate strata within the TARGIT-A trial.
The fi rst results of the TARGIT-A trial6 (n=2232) showed that local recurrence with TARGIT 
was non-inferior to EBRT.
Interpretation
Randomisation in the TARGIT-A trial was continued while the data matured and the trial was 
closed after 3451 patients were accrued. This preplanned analysis provides more mature 
data than previously reported: the number of local recurrences increased from 13 to 34 and 
there were 88 deaths.
This is the fi rst analysis of deaths and of the two strata as per timing of delivery of 
TARGIT. We showed that in comparison with several weeks of conventional whole 
breast radiotherapy, all breast cancer outcomes are much the same when single-dose 
TARGIT is delivered concurrently with lumpectomy (n=2298). However, when TARGIT is 
delivered as a second procedure by reopening the wound, despite tighter case selection 
(n=1143), the local recurrence rate was higher than with EBRT. We also showed that in 
the TARGIT group, there was a signifi cant reduction in deaths from causes other than 
breast cancer (17 vs 35), attributable to fewer deaths from cardiovascular causes or 
other cancers.
TARGIT concurrent with lumpectomy within a risk-adapted approach should be considered 
as an option for eligible patients with breast cancer carefully selected as per the TARGIT-A 
trial protocol, as an alternative to postoperative external beam breast radiotherapy.
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e-table 1: Patient and tumour characteristics The denominator for unknown percentages is the total number randomised 
(1721 and 1730) and the denominator for each category is the total number of known cases. Most of the unknown data is 
from the 342 patients randomised in the last 6 months before data lock. The bar chart (bottom) gives a summary of the data. 
Totals of percentages of known may not add up to 100 due to rounding. 
 
   TARGIT (1721) EBRT (1730)  
Age (years)   p=0.274 
<=50  150 9% 122 7%  
51-60  527 31% 548 32%  
61-70  781 45% 807 47%  
>70  263 15% 253 15%  
        
Pathological tumour size      p=0.273 
<=1cm  611 39% 597 39%  
1.1-2cm  751 48% 726 48%  
>2cm  190 12% 207 14%  
Unknown  169 10 % 200 12 %  
Grade      p=0.394 
1  528 35% 558 37%  
2  757 50% 720 48%  
3  232 15% 227 15%  
Unknown  194 11% 225 13%  
Lymphovascular invasion      p=0.224 
Absent  1348 87% 1343 88%  
Present  194 13% 178 12%  
Unknown  179 10% 209 12%  
Nodes involved      p=0.091 
      0  1307 83% 1303 85%  
    1-3  219 14% 211 14%  
    >3  43 3% 29 2%  
Unknown  152 9% 187 11%  
ER status      p=0.090 
ER +ve  1441 92% 1433 94%  
ER -ve  120 8% 99 7%  
ER Unknown  160 9% 198 12%  
PgR status      p=0.179 
PgR +ve  1232 81 % 1230 82%  
PgR -ve  289 19 % 265 18%  
PgR Unknown  200 12% 235 14%  
HER 2 receptor      p=0.585 
Positive  170 11% 178 12%  
Negative  1329 89% 1309 88%  
Unknown  222 13% 243 14%  
 
   
  
 
  
e-table 2: Unplanned post-hoc exploratory non-randomised comparison of tumour characteristics and primary and 
secondary outcomes as per treatment received amongst those who were randomised to TARGIT and received the 
allocated treatment. Percentages are of the known values.  
 Prepathology 
patients who 
received 
TARGIT Alone  
N=793 
Prepathology 
patients who 
received 
TARGIT+EBRT 
N=219 
Postpathology 
patients who 
received 
TARGIT Alone 
N=539 
T size    
 <=1cm 36% (256/703) 24% (47/199) 52% (269/515) 
 1-2 cm 52% (366/703) 49% (98/199) 43% (223/515) 
 >2cm 12% (81/703) 27% (54/199) 5% (23/515) 
Grade    
 Grade 1 27%(188/707) 19% (38/200) 59% (285/486) 
 Grade 2 54%(380/707) 60.5% (121/200) 38% (182/486) 
 Grade 3 20%(139/707) 20.5% (41/200) 4% (19/486) 
Lymph node positivity    
 Node negative 85% (604/712) 63% (126/201) 95% (492/519) 
 1-3 nodes involved 13% (94/712) 29% (59/201) 5% (27/519) 
 >3 nodes involved 2% (14/712) 8% (16/201) 0 (0/519) 
    
5-year Local recurrence in the conserved breast (95%CI) 2.7 (1.3-5.5) 0.9 (0.1-6.1) 5.9 (3.3-10.5) 
5-year risk of Breast cancer death (95%CI) 1.8 (0.7-4.6) 8.0 (3.5-17.5) 0.6 (0.2-2.5) 
5-year risk of Deaths from other causes (95%CI) 1.9 (0.9-4.0) 0  1.5 (0.6-4.3) 
N.B. Only 20 postpathology patients received TARGIT+EBRT and therefore their data is not given.  
!
 
 
 
e-table 3 Complications 6 months after randomisation 
 
 TARGIT EBRT 
Wound related complications   
Haematoma / Seroma requiring more than 3 aspirations or surgery 4 2 
Wound infection requiring intravenous antibiotics or surgery 12 9 
Skin breakdown / Delayed wound healing 3 5 
Total 19  
(1.1%) 
16  
(0.9%) 
 p=0.599 
Radiotherapy related complications   
Radiation Therapy Oncology Group (RTOG) 
 Grade 3 or 4 radiotherapy toxicity 
4 
(0.2%) 
13 
(0.8%) 
 p=0.029 
  
eFigure 1 Trial summary: Schema for the TARGIT-A randomised trial comparing risk-adapted radiotherapy with 
conventional whole breast radiotherapy.  
 
 
 
Eligibility:  
Age >=45 years  
Unifocal invasive ductal carcinoma preferably <3.5cm 
(MRI not required) 
Suitable for breast conserving surgery 
 
Stratification prior to randomisation  
 
Diagnosis  established by needle biopsy and the 
patient has NOT had excision of cancer 
 
Prepathology stratum 
 
-- If randomised to TARGIT 
TARGIT given concurrently with lumpectomy 
-- If randomised to EBRT  
EBRT given as usual after lumpectomy 
 
n=2298 
Risk-adapted radiotherapy 
TARGeted Intraoperative radioTherapy 
(TARGIT) 
focussed to the tumour bed and delivered in a 
single dose with Intrabeam 
If high risk factors are found on final 
pathology, EBRT should be  added  
n= 1140 
One-size fits all radiotherapy 
Standard fractionated whole breast   
Exteral Beam RadioTherapy (EBRT) 
n=1158 
 
Diagnosis is established and the patient has 
already had excision of cancer  
 
Postpathology stratum  
 
-- If randomised to TARGIT 
TARGIT given as a delayed procedure  
by re-opening the wound 
-- If randomised to EBRT  
EBRT given as usual after lumpectomy 
n=1153 
 
Risk-adapted radiotherapy 
TARGeted Intraoperative radioTherapy 
(TARGIT) 
focussed to the tumour bed and delivered in a 
single dose with Intrabeam 
If high risk factors are found on final 
pathology, EBRT should be  added 
n=581 
 
One-size fits all radiotherapy 
Standard fractionated whole breast   
Exteral Beam RadioTherapy (EBRT) 
n=572 
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eFigure 2 The TARGIT technique The Intrabeam device (top left) and a schematic diagram showing how the spherical 
applicator fits into the tumour bed (top right). Intraoperative radiotherapy being delivered in the operation theatre (bottom 
left) and a close up of the spherical applicator in the tumour bed (bottom right) !  
!50 kV X-ray  
Source 
Articulated 
stand 
 
eFigure 3: Consort diagram (top) and completeness of follow up (bottom) showing the observed and expected follow 
up for the whole trial cohort. 
 
 
* protocol deviations: 78/1721 (4.5%) patients allocated TARGIT received EBRT and 12/1730 (0.7%) allocated 
EBRT received TARGIT  
** 239/1721 (13.8%) patients allocated TARGIT received EBRT after TARGIT as per protocol and 239/1571 
(15.2%) as per treatment received 
 
3451 patients enrolled and randomised 
 
 
1721 Allocated to TARGIT with or without EBRT 
 
 9 withdrawn 
 
141 did not receive allocated   
 treatment 
78 received EBRT* 
42  had a mastectomy 
21 did not receive TARGIT or EBRT 
 
1571 received allocated treatment 
     1332 received TARGIT 
     239 received TARGIT and EBRT** 
 
1679 included in analysis of breast 
 recurrence 
   (42  had a mastectomy) 
1721 included in analysis of death 
1730 Allocated to EBRT 
27 withdrawn 
 
113 did not receive allocated 
 treatment 
12 received TARGIT* 
14 received TARGIT and EBRT 
34 had a mastectomy 
53 did not receive TARGIT or EBRT 
 
1590 received allocated treatment 
  
1696 included in analyis of breast   
 recurrence 
   (34 had a mastectomy) 
1730 included in analysis of death 
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eFigure 4: Consort diagram for the prepathology (top) and postpathology (bottom) strata 
 
* protocol deviations': 67/1140 (5.9%) patients allocated TARGIT received EBRT and 10/1158 (0.9%) allocated EBRT received 
TARGIT .   
** 219/1140 (19.2%) patients allocated TARGIT received EBRT after TARGIT as per protocol, and 219/1012 (21.6%) as per 
treatment received 
 
 
* ‘protocol deviations': 11/581 (1.9%) patients allocated TARGIT received EBRT and 2/572 (0.3%) allocated EBRT received TARGIT  
**  20/581 (3.4%) patients allocated TARGIT received EBRT after TARGIT as per protocol, and 20/559 (3.6%) as per treatment 
received 
Prepathology:  2298 patients enrolled and randomised before excision of cancer 
 
 
1140 Allocated to TARGIT with or without EBRT 
 
 8 withdrawn 
 
120 did not receive allocated treatment 
67 received EBRT* 
33  had a mastectomy 
20 did not receive TARGIT or EBRT 
 
1012 received allocated treatment 
     793 received TARGIT 
     219 received TARGIT and EBRT** 
1107 included in analysis of breast recurrence 
   (33  had a mastectomy) 
1140 included in analysis of death 
1158 Allocated to EBRT 
21 withdrawn 
 
98 did not receive allocated treatment 
10 received TARGIT* 
8 received TARGIT and EBRT 
31 had a mastectomy 
49 did not receive TARGIT or EBRT 
 
1039 received allocated treatment 
1127 included in analyis of breast recurrence 
   (31 had a mastectomy) 
1158 included in analysis of death 
 
Postpathology: 1153 patients enrolled and randomised after excision of cancer 
 
 
581 Allocated to TARGIT with or without EBRT 
 
 1 withdrawn 
 
21 did not receive allocated    treatment 
11 received EBRT* 
9  had a mastectomy 
1  did not receive TARGIT or EBRT 
 
559 received allocated treatment 
     539 received TARGIT 
     20 received TARGIT and EBRT** 
572 included in analysis of breast recurrence 
   (9  had a mastectomy) 
581 included in analysis of death 
572 Allocated to EBRT 
6  withdrawn 
 
15 did not receive allocated  treatment 
2 received TARGIT* 
6 received TARGIT and EBRT 
3 had a mastectomy 
4 did not receive TARGIT or EBRT 
 
551 received allocated treatment 
569 included in analyis of breast recurrence 
   (3 had a mastectomy) 
572 included in analysis of death 
 
eFigure 5: Primary and secondary outcomes for the Prepathology stratum (n=2298, randomised before lumpectomy and 
TARGIT given concurrently with lumpectomy): Kaplan-Meier plots for local recurrence in the conserved breast (top) in 
patients who had breast conserving surgery, for breast cancer deaths and non-breast-cancer deaths in all patients(middle 
and bottom) Blue: TARGIT and Red: EBRT. The top graph is the same as in figure 3A – reproduced here for context. 
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Local recurrence in the conserved breast
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